Shop
Niraparib / Zejula (Everest)
Original price was: £344.00.£244.00Current price is: £244.00.Niraparib (also known as Niraparib; Brand name: Zejula) is a PARP inhibitor used for maintenance treatment of advanced recurrent ovarian cancer.
Niraparib has been shown to significantly prolong progression-free survival and help reduce the risk of ovarian cancer recurrence in patients with advanced disease.
MedFind provides overseas sourcing services for Niraparib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Learn more about indications, side effects, and medication guidance.
Olaparib (brand name: Lynparza, Lipuzhuo; Beacon).
Price range: £468.00 through £591.00Olaparib produced by Beacon (generic name: Olaparib; brand names: Lynparza, Lipuzhuo) is a PARP inhibitor originally developed by AstraZeneca. It has been approved by the FDA for the treatment of various cancers, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
It works by inhibiting DNA repair enzymes, preventing cancer cells from repairing their DNA, which leads to cell death and helps delay or stop tumor progression.
Beacon Pharmaceuticals was founded in 2001 and is one of the largest and most technologically advanced manufacturers of oncology and antiviral drugs in Bangladesh. Its products comply with international GMP certifications, including those from the US FDA, UK MHRA, and Australia’s TGA.
Olaparib / Lynparza (Everest)
Price range: £163.00 through £325.00Olaparib (also known as Olaparib; Brand name: Lynparza) is a PARP inhibitor used for the treatment of ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
In addition to its approved indications, Olaparib has shown promising efficacy across multiple tumor types and is increasingly recognized for its potential as a broad-spectrum targeted anticancer therapy.
MedFind provides overseas sourcing services for Olaparib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Osimertinib (brand name: Tagrisso, Terisha; Incepta).
Original price was: £288.00.£97.00Current price is: £97.00.由 Incepta 公司生产的奥希替尼是一种第三代口服不可逆 EGFR 靶向酪氨酸激酶抑制剂 (EGFR-TKI)，由英国阿斯利康公司开发。其原商品名为泰瑞沙 (Tagrisso)，研发代号为 AZD9291。
它用于治疗晚期非小细胞肺癌（NSCLC），并选择性地抑制 EGFR 敏感突变和 EGFR T790M 耐药突变。
Osimertinib / Tagrisso (Everest)
Original price was: £108.00.£91.00Current price is: £91.00.Osimertinib (Brand name: Tagrisso) is a third-generation oral, irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) originally developed by AstraZeneca under the research code AZD9291.
It is used for the treatment of advanced non-small cell lung cancer (NSCLC) and selectively targets both EGFR-sensitive mutations and the EGFR T790M resistance mutation.
Osimertinib (Tagrisso) received approval for import and clinical use in China in March 2017.
Ponatinib (Everest)
Price range: £174.00 through £312.00Ponatinib (Brand name: ICLUSIG) is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI) used for the treatment of chronic myeloid leukemia (CML) with the ABL T315I mutation and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
It is also indicated for patients with CML or ALL who are resistant to or intolerant of previous tyrosine kinase inhibitor therapies.
MedFind provides overseas sourcing services for Ponatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Sotorasib / Lumakras (Everest)
Original price was: £450.00.£391.00Current price is: £391.00.Sotorasib, also known as Sotororese (generic name: Sotorasib, brand name: Lumakras, code name: AMG510), is a covalent inhibitor of the KRAS G12C mutant. It binds to the KRAS G12C mutant protein, locking KRAS in its inactive state and thereby irreversibly inhibiting its activity.
Clinical trial results showed that patients treated with Sotorasib achieved an overall response rate (ORR) of 36% (95% CI: 28–45), a disease control rate (DCR) of 81% (95% CI: 73–87), and a median duration of response of 10 months. After more than 40 years of research on KRAS-mutant oncogenic proteins, Sotorasib became the world’s first approved KRAS G12C inhibitor.
Tucatinib (also translated as Tukatinib; brand name: Tukysa, Everest)
Original price was: £790.00.£570.00Current price is: £570.00.Tucatinib (also translated as Tukatinib; brand name: Tukysa) is able to inhibit the growth of tumor cells that overexpress HER2.
In 2020, the U.S. FDA approved tucatinib in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have previously received one or more anti-HER2-based treatment regimens.
Venetoclax / Venclexta (Everest)
Original price was: £300.00.£256.00Current price is: £256.00.Venetoclax (also known as Venetoclax; Brand name: Venclexta) is the first selective targeted therapy designed to inhibit the B-cell lymphoma-2 (BCL-2) protein, helping promote apoptosis in cancer cells and suppress tumor survival.
MedFind provides overseas sourcing services for Venetoclax through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.